{"page_content": "BRIGHTER FUTURES  |  2019 CSR Report29\nAbout           +           Serve                        Transform                        Advance          +           Redefine           +           Ethics & Compliance           +           Reporting Index           \nCOMMUNICATING the \nEFFICACY AND SAFETY  \nOF OUR MEDICINES  \nAlexion is committed to safely and effectively \ndelivering our transformative medicines to patients and customers. We do this in a way  \nthat protects the patient and meets the requirements and expectations of all of our key stakeholders, including global regulatory agencies, local governments and laws.\nIn 2019, we established an aspiration  \nto generate real-world evidence to  \ndocument the benefits and safety  \nof Alexion treatments, and we\u2019re  \npleased to report our ongoing progress: \n\u2022\n P\narticipated in 55 Congresses \n\u2022\n \nSubmitted 98 abstracts; 97% accepted\n\u2022\n \nGave 24 oral presentations \n\u2022\n \nDeveloped 70 posters \n\u2022\n \nSubmitted 44 manuscripts \n\u2022\n \nPublished 32 manuscripts \n\u2022\n \nDelivered 11 medical symposia \n\u2022\n \nReached 3,000+ medical symposia \nattendees\n\u2022\n P\nrepared 4 plain-language summaries  \nof manuscripts (1 published; 3 under  \njournal review) \n\u2022\n Cr\neated 9 posters around  \nplain-language summaries A FOUNDATION OF QUALITY\nAt Alexion, we believe that quality is for everyone, \nin accordance with our CSR-STAR foundation of ethics and compliance (see Page 46). Explicitly stated in our Quality Policy , this means that each \nAlexion employee is accountable for integrating quality into what we do every day through the decisions we make and actions we take.\nWe require all Alexion employees and \ncontractors to attest to upholding the  \nfive tenets of our Quality Policy:1:\n Deliv\nering safe and effective medicines that \nmeet or exceed the requirements of our patients and our customers.\n2: Complying with all applicable regulatory   \n requirements.\n3: Operating a Quality Management System    \n and improving our systems and processes.\n4: Ensuring the integrity of our data.\n5: Upholding our individual and collective  \n accountability for quality.PROJECT \nGENESIS:  \nGENERATING EVIDENCE\nAs patients face increasing challenges in \naccessing highly specialized treatments, it is \nimperative that Alexion adapts quickly. In 2019, \nour Global Medical Affairs team initiated Project \nGenesis to develop enterprise-wide evidence \ngeneration capabilities to support the approval \nof and reimbursement for therapies. With \ninput from Alexion stakeholders, as well as \ninsights from external experts, best-in-class \nbenchmarks and scientific research, \nProject Genesis is enabling Alexion \nto optimize patient access to \nour therapies.", "metadata": {"source": "NASDAQ_ALXN_2019.pdf", "page": 28, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}